Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair. Ballout F, Lu H, Bhat N, Chen L, et al. Clin Cancer Res 2024;30:2193-2205.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ballout F, Lu H, Bhat N, Chen L, et al. Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair. Clin Cancer Res 2024;30:2193-2205.
PMID: 38592373